The rise of robotic diagnostics infrastructure
Vitestro’s $70 million bet on automated blood testing
Dutch medical robotics company Vitestro raised $70 million in Series B funding on 10 March 2026, underscoring a growing push to automate the infrastructure behind diagnostic testing. The Utrecht-based startup is developing Aletta, an autonomous robotic system designed to perform venous blood draws using imaging technology, robotics and artificial intelligence. The financing round—backed by investors including the venture funds of Mayo Clinic, Labcorp and Sutter Health—will support manufacturing scale-up, clinical expansion and regulatory work ahead of broader deployment.
The announcement places Vitestro at the centre of a broader shift in healthcare: the gradual automation of diagnostic workflows. As hospitals face rising demand for testing and persistent shortages of specialised staff, robotics is beginning to move beyond laboratory automation into the earliest step of the diagnostic process—collecting the sample itself.
Vitestro’s Aletta device combines imaging technologies such as near-infrared scanning and ultrasound with artificial intelligence software to identify veins and guide needle insertion before collecting blood samples. The company is pursuing regulatory clearance in the United States while expanding clinical development in Europe.
For investors and healthcare providers, the interest in robotic phlebotomy reflects a wider question: how much of diagnostic medicine can be automated without compromising safety, reliability or patient trust?
Diagnostics: a critical but overstretched healthcare system
Diagnostic testing sits at the centre of modern medicine. Blood tests, imaging scans and laboratory analyses influence a large proportion of clinical decisions.
Yet the infrastructure that supports these tests—sample collection, preparation and laboratory processing—remains heavily dependent on manual labour.
Healthcare systems are under increasing operational pressure. Ageing populations, expanded screening programmes and advances in precision medicine are driving higher testing volumes. At the same time, hospitals across Europe and North America face shortages of trained laboratory professionals and phlebotomists.
Automation is therefore becoming a strategic priority.
Robotics systems can perform repetitive tasks such as sample handling, liquid transfer and laboratory preparation with high levels of precision and consistency. These systems reduce operational bottlenecks and allow clinicians to focus on patient care rather than routine procedures.
Researchers increasingly describe this shift as automated diagnostic ecosystems—integrated systems in which robotics, software and clinicians work together to manage the flow of patient samples from collection to analysis.
Vitestro’s technology attempts to extend automation to the very beginning of that diagnostic pipeline.
Automating one of healthcare’s most common procedures
Drawing blood—known medically as venipuncture—is one of the most frequently performed procedures in healthcare. Billions of blood samples are collected globally each year.
Despite its routine nature, the process requires skill and experience. Phlebotomists must identify suitable veins, insert needles accurately and ensure samples are handled correctly to avoid contamination or diagnostic errors.
Failed attempts are not uncommon. Difficult venous access, operator variability or patient anxiety can lead to repeated insertions and delays in testing.
Vitestro’s robotic system aims to standardise the procedure.
The Aletta platform scans the patient’s arm using near-infrared imaging to detect veins beneath the skin. Ultrasound imaging then assesses the depth and quality of the vessel before a robotic arm performs the puncture. The system monitors the procedure in real time and automatically fills the required sample tubes.
The technology could reduce variability in blood collection while allowing clinical staff to focus on more complex medical tasks.
Even if robotic blood collection becomes widely adopted, hospitals are likely to deploy such systems alongside trained clinicians rather than replacing them entirely.
Robotics already powers modern diagnostic laboratories
While robotic blood collection is still emerging, automation already plays a central role in modern diagnostic laboratories.
Major diagnostics companies such as Roche Diagnostics, Abbott Laboratories and Siemens Healthineers have developed integrated laboratory automation systems capable of processing large volumes of samples.
In many hospital laboratories, robotic systems transport test tubes, prepare reagents and perform repetitive analytical procedures.
Automation is particularly important in liquid handling, where extremely small quantities of biological material must be transferred with high precision. Robotic liquid-handling systems are widely used in diagnostics, genomics and pharmaceutical research because they deliver consistent results at scale.
These systems often operate behind the scenes but form the operational backbone of high-throughput diagnostic laboratories.
The next frontier is extending automation beyond the laboratory and into earlier stages of the diagnostic process.
Startups are extending robotics across the diagnostic pipeline
A new generation of startups is exploring how robotics and artificial intelligence can transform multiple stages of diagnostics—from imaging to laboratory analysis.
Robotic ultrasound
Researchers and early-stage companies are developing robotic ultrasound systems capable of performing diagnostic scans with limited human intervention.
These systems combine robotic arms with computer vision and artificial intelligence algorithms that automatically identify anatomical landmarks and capture diagnostic images.
The goal is not simply automation but accessibility. Ultrasound imaging requires trained technicians, and shortages of sonographers limit access to diagnostic imaging in many healthcare systems.
Robotic ultrasound could expand access to imaging in rural clinics, emergency settings and regions where specialist expertise is scarce.
Robotic laboratories
Automation is also advancing inside research and clinical laboratories.
Robotics-driven laboratory platforms combine automated liquid-handling systems with software that coordinates experiments and records results. These systems can automate complex workflows such as sample preparation, biological assays and experimental analysis.
In research environments where thousands of biological samples must be analysed, laboratory robotics can dramatically increase experimental throughput while improving reproducibility.
This capability is particularly valuable in diagnostics development, biotechnology research and pharmaceutical discovery.
AI-driven diagnostic analysis
Automation in diagnostics increasingly involves software as well as robotics.
Artificial intelligence systems are now being used to analyse medical images, interpret genomic data and detect patterns that may indicate disease.
In fields such as cancer diagnostics, advanced computing infrastructure can analyse large genomic datasets and identify clinically relevant mutations far more quickly than traditional workflows.
These technologies represent another layer of the same transformation: automation of diagnostic data analysis.
Together, robotics and AI are gradually turning diagnostics into an integrated technological system.
Industry analysis: diagnostics is becoming an automation platform
The growing interest in robotic diagnostics reflects a deeper shift in healthcare technology.
For decades, innovation in diagnostics focused on improving the accuracy of individual tests.
Today, the challenge is increasingly operational.
Healthcare systems must process vast numbers of diagnostic tests while maintaining speed, reliability and consistency. The bottleneck is often not the diagnostic technology itself but the workflow connecting different parts of the system.
Automation addresses this problem.
Robotics standardises physical procedures such as sample collection and handling. Artificial intelligence accelerates data interpretation. Digital systems connect diagnostic instruments, patient records and laboratory results.
The result is the emergence of diagnostic infrastructure platforms.
Startups entering this field are not necessarily inventing new medical tests. Instead, they are building the automated systems that allow those tests to scale efficiently.
Vitestro’s robotic phlebotomy platform is one example of this emerging category.
If automated blood collection proves reliable in clinical environments, it could remove one of the most persistent operational bottlenecks in diagnostic medicine.
The limits of automation
Despite growing investment, robotics in diagnostics still faces several barriers.
Regulation remains a significant challenge. Medical robotics systems must undergo extensive clinical validation before they can be widely deployed.
Healthcare providers are also cautious when introducing automation into patient-facing procedures. Technologies such as robotic blood collection must demonstrate not only technical reliability but also patient safety and acceptance.
Cost is another consideration. Installing robotic systems can require changes to hospital workflows and infrastructure.
For these reasons, automation in diagnostics is likely to expand gradually rather than through sudden disruption.
The next layer of healthcare infrastructure
Vitestro’s $70 million funding round reflects a growing recognition that diagnostics requires more than better tests—it requires better systems.
Robotics already powers large parts of the modern laboratory. Artificial intelligence is accelerating the interpretation of medical data. Startups are now targeting the earliest stages of the diagnostic workflow, from blood collection to imaging.
What is emerging is not a single breakthrough technology but a new layer of healthcare infrastructure.
Hospitals are beginning to adopt systems that treat diagnostics as an operational network—where samples, data and analysis move through automated workflows designed for speed, consistency and scale.
If these technologies prove reliable in real clinical environments, the impact could extend far beyond individual devices.
The next transformation in healthcare diagnostics may not come from discovering a new medical test.
It may come from rebuilding the system that delivers those tests in the first place.
Liked this article? You can support our independent journalism via our page on Buy Me a Coffee. It helps keep MoveTheNeedle.news focused on depth, not clicks.